Literature DB >> 28605029

The pancreatic cancer microenvironment: A true double agent.

Laleh G Melstrom1, Marcela D Salazar2, Don J Diamond2.   

Abstract

The tumor microenvironment in pancreatic cancer is a complex balance of pro- and anti-tumor components. The dense desmoplasia consists of immune cells, extracellular matrix, growth factors, cytokines, and cancer associated fibroblasts (CAF) or pancreatic stellate cells (PSC). There are a multitude of targets including hyaluronan, angiogenesis, focal adhesion kinase (FAK), connective tissue growth factor (CTGF), CD40, chemokine (C-X-C motif) receptor 4 (CXCR-4), immunotherapy, and Vitamin D. The developing clinical therapeutics will be reviewed.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  focal adhesion kinase; hedgehog inhibitors; hyaluronan; immunotherapy; tumor microenvironment; vitamin D

Mesh：

Substances：

Year:  2017        PMID： 28605029      PMCID： PMC5989710          DOI： 10.1002/jso.24643

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN： 0022-4790            Impact factor:   3.454


  121 in total

1.  Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer.

Authors:  Marina Lesina; Magdalena U Kurkowski; Katharina Ludes; Stefan Rose-John; Matthias Treiber; Günter Klöppel; Akihiko Yoshimura; Wolfgang Reindl; Bence Sipos; Shizuo Akira; Roland M Schmid; Hana Algül
Journal:  Cancer Cell       Date:  2011-04-12       Impact factor: 31.743

Review 2.  Pancreatic cancer stroma: understanding biology leads to new therapeutic strategies.

Authors:  Agnieszka Anna Rucki; Lei Zheng
Journal:  World J Gastroenterol       Date:  2014-03-07       Impact factor: 5.742

3.  Expression of transforming growth factor-beta 1 by pancreatic stellate cells and its implications for matrix secretion and turnover in chronic pancreatitis.

Authors:  Fanny Wai-Tsing Shek; Robert Christopher Benyon; Fiona Mairi Walker; Peter Raymond McCrudden; Sylvia Lin Foon Pender; Elizabeth Jean Williams; Penelope Ann Johnson; Colin David Johnson; Adrian Calvin Bateman; David Roger Fine; John Peter Iredale
Journal:  Am J Pathol       Date:  2002-05       Impact factor: 4.307

4.  Trefoil factor 1 stimulates both pancreatic cancer and stellate cells and increases metastasis.

Authors:  Thiruvengadam Arumugam; Will Brandt; Vijaya Ramachandran; Tood T Moore; Huamin Wang; Felicity E May; Bruce R Westley; Rosa F Hwang; Craig D Logsdon
Journal:  Pancreas       Date:  2011-08       Impact factor: 3.327

5.  Macropinocytosis of Nab-paclitaxel Drives Macrophage Activation in Pancreatic Cancer.

Authors:  Jane Cullis; Despina Siolas; Antonina Avanzi; Sugata Barui; Anirban Maitra; Dafna Bar-Sagi
Journal:  Cancer Immunol Res       Date:  2017-01-20       Impact factor: 11.151

6.  Pancreatic stellate cells: partners in crime with pancreatic cancer cells.

Authors:  Alain Vonlaufen; Swapna Joshi; Changfa Qu; Phoebe A Phillips; Zhihong Xu; Nicole R Parker; Cheryl S Toi; Romano C Pirola; Jeremy S Wilson; David Goldstein; Minoti V Apte
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

7.  Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase.

Authors:  Catherine Uyttenhove; Luc Pilotte; Ivan Théate; Vincent Stroobant; Didier Colau; Nicolas Parmentier; Thierry Boon; Benoît J Van den Eynde
Journal:  Nat Med       Date:  2003-09-21       Impact factor: 53.440

8.  Production and effects of endothelin-1 in rat pancreatic stellate cells.

Authors:  Hanne Klonowski-Stumpe; Roland Reinehr; Richard Fischer; Ulrich Warskulat; Reinhard Lüthen; Dieter Häussinger
Journal:  Pancreas       Date:  2003-07       Impact factor: 3.327

9.  Losartan slows pancreatic tumor progression and extends survival of SPARC-null mice by abrogating aberrant TGFβ activation.

Authors:  Shanna A Arnold; Lee B Rivera; Juliet G Carbon; Jason E Toombs; Chi-Lun Chang; Amy D Bradshaw; Rolf A Brekken
Journal:  PLoS One       Date:  2012-02-14       Impact factor: 3.240

10.  Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy.

Authors:  Hong Jiang; Samarth Hegde; Brett L Knolhoff; Yu Zhu; John M Herndon; Melissa A Meyer; Timothy M Nywening; William G Hawkins; Irina M Shapiro; David T Weaver; Jonathan A Pachter; Andrea Wang-Gillam; David G DeNardo
Journal:  Nat Med       Date:  2016-07-04       Impact factor: 53.440
View more
  23 in total

1.  The impact of immunotherapy on the survival of pancreatic adenocarcinoma patients who do not receive definitive surgery of the tumor.

Authors:  Saber Amin; Michael Baine; Jane Meza; Morshed Alam; Chi Lin
Journal:  Clin Transl Radiat Oncol       Date:  2020-06-07

Review 2.  Advances in Tumor-Stroma Interactions: Emerging Role of Cytokine Network in Colorectal and Pancreatic Cancer.

Authors:  Chiara Bazzichetto; Fabiana Conciatori; Italia Falcone; Francesco Cognetti; Michele Milella; Ludovica Ciuffreda
Journal:  J Oncol       Date:  2019-05-05       Impact factor: 4.375

3.  Tumoral EHF predicts the efficacy of anti-PD1 therapy in pancreatic ductal adenocarcinoma.

Authors:  Jing Liu; Wenna Jiang; Kaili Zhao; Hongwei Wang; Tianxing Zhou; Weiwei Bai; Xiuchao Wang; Tiansuo Zhao; Chongbiao Huang; Song Gao; Tai Qin; Wenwen Yu; Bo Yang; Xin Li; Danqi Fu; Wei Tan; Shengyu Yang; He Ren; Jihui Hao
Journal:  J Exp Med       Date:  2019-02-07       Impact factor: 14.307

Review 4.  Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches.

Authors:  Michael Orth; Philipp Metzger; Sabine Gerum; Julia Mayerle; Günter Schneider; Claus Belka; Maximilian Schnurr; Kirsten Lauber
Journal:  Radiat Oncol       Date:  2019-08-08       Impact factor: 3.481

5.  Verteporfin- and sodium porfimer-mediated photodynamic therapy enhances pancreatic cancer cell death without activating stromal cells in the microenvironment.

Authors:  Jingjing Lu; Bhaskar Roy; Marlys Anderson; Cadman L Leggett; Michael J Levy; Brian Pogue; Tayyaba Hasan; Kenneth K Wang
Journal:  J Biomed Opt       Date:  2019-11       Impact factor: 3.170

Review 6.  Emerging Kinase Therapeutic Targets in Pancreatic Ductal Adenocarcinoma and Pancreatic Cancer Desmoplasia.

Authors:  Justin F Creeden; Khaled Alganem; Ali S Imami; Nicholas D Henkel; F Charles Brunicardi; Shi-He Liu; Rammohan Shukla; Tushar Tomar; Faris Naji; Robert E McCullumsmith
Journal:  Int J Mol Sci       Date:  2020-11-21       Impact factor: 5.923

Review 7.  Novel Anticancer and Treatment Sensitizing Compounds against Pancreatic Cancer.

Authors:  Gabrielle Wishart; Priyanka Gupta; Andrew Nisbet; Eirini Velliou; Giuseppe Schettino
Journal:  Cancers (Basel)       Date:  2021-06-11       Impact factor: 6.639

8.  Inhibition of de novo pyrimidine synthesis augments Gemcitabine induced growth inhibition in an immunocompetent model of pancreatic cancer.

Authors:  Thuy Phan; Vu H Nguyen; Ralf Buettner; Corey Morales; Lifeng Yang; Paul Wong; Weiman Tsai; Marcela d'Alincourt Salazar; Ziv Gil; Don J Diamond; Joshua D Rabinowitz; Steven Rosen; Laleh G Melstrom
Journal:  Int J Biol Sci       Date:  2021-06-01       Impact factor: 6.580

Review 9.  Immune Cell Modulation of the Extracellular Matrix Contributes to the Pathogenesis of Pancreatic Cancer.

Authors:  Ramiz S Ahmad; Timothy D Eubank; Slawomir Lukomski; Brian A Boone
Journal:  Biomolecules       Date:  2021-06-17

10.  TCF7L2 positively regulates aerobic glycolysis via the EGLN2/HIF-1α axis and indicates prognosis in pancreatic cancer.

Authors:  Jinfeng Xiang; Qiangsheng Hu; Yi Qin; Shunrong Ji; Wenyan Xu; Wensheng Liu; Si Shi; Chen Liang; Jiang Liu; Qingcai Meng; Dingkong Liang; Quanxing Ni; Jin Xu; Bo Zhang; Xianjun Yu
Journal:  Cell Death Dis       Date:  2018-02-23       Impact factor: 8.469
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.